You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

Investigational Drug Information for Serlopitant


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Serlopitant?

Serlopitant is an investigational drug.

There have been 12 clinical trials for Serlopitant. The most recent clinical trial was a Phase 3 trial, which was initiated on August 29th 2018.

The most common disease conditions in clinical trials are Pruritus, Prurigo, and Neurodermatitis. The leading clinical trial sponsors are Menlo Therapeutics Inc., Vyne Therapeutics Inc., and Epidermolysis Bullosa Research Partnership.

There are twenty-one US patents protecting this investigational drug and eighty-three international patents.

Recent Clinical Trials for Serlopitant
TitleSponsorPhase
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaEpidermolysis Bullosa Research PartnershipPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaMenlo TherapeuticsPhase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaStanford UniversityPhase 2

See all Serlopitant clinical trials

Clinical Trial Summary for Serlopitant

Top disease conditions for Serlopitant
Top clinical trial sponsors for Serlopitant

See all Serlopitant clinical trials

US Patents for Serlopitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Serlopitant ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Serlopitant ⤷  Sign Up ⤷  Sign Up
Serlopitant ⤷  Sign Up Use of NK-1 receptor antagonist serlopitant in pruritus Menlo Therapeutics Inc. (Redwood, CA) ⤷  Sign Up
Serlopitant ⤷  Sign Up Use of NK-1 receptor antagonist serlopitant in pruritus MENLO THERAPEUTICS INC. (Redwood City, CA) ⤷  Sign Up
Serlopitant ⤷  Sign Up Use of NK-1 receptor antagonists in pruritus MENLO THERAPEUTICS INC. (Redwood City, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Serlopitant

Drugname Country Document Number Estimated Expiration Related US Patent
Serlopitant Australia AU2017261372 2036-05-05 ⤷  Sign Up
Serlopitant Canada CA3023278 2036-05-05 ⤷  Sign Up
Serlopitant China CN107847398 2036-05-05 ⤷  Sign Up
Serlopitant European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Serlopitant European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.